FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W88596619> ?p ?o ?g. }

• W88596619 endingPage "1141" @default.
• W88596619 startingPage "1141" @default.
• W88596619 abstract "Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4 Mengshu Wang,1* Yong Zhang,1* Jiao Feng,1 Tiejun Gu,1 Qingguang Dong,1 Xu Yang,2 Yanan Sun,1 Yongge Wu,1 Yan Chen,1 Wei Kong1 1National Engineering Laboratory for AIDS Vaccine, College of Life Science, Jilin University, Changchun, People’s Republic of China; 2BCHT Biopharm Co, Ltd, Changchun, People’s Republic of China*These authors contributed equally to this workBackground: Exendin-4 is an incretin mimetic agent approved for type 2 diabetes treatment. However, the required frequent injections restrict its clinical application. Here, the potential use of chitosan-coated poly (d,l-lactide-co-glycolide) (CS-PLGA) nanoparticles was investigated for intestinal delivery of exendin-4.Methods and results: Nanoparticles were prepared using a modified water–oil–water (w/o/w) emulsion solvent-evaporation method, followed by coating with chitosan. The physical properties, particle size, and cell toxicity of the nanoparticles were examined. The cellular uptake mechanism and transmembrane permeability were performed in Madin-Darby canine kidney-cell monolayers. Furthermore, in vivo intraduodenal administration of exendin-4-loaded nanoparticles was carried out in rats. The PLGA nanoparticle coating with chitosan led to a significant change in zeta potential, from negative to positive, accompanied by an increase in particle size of ~30 nm. Increases in both the molecular weight and degree of deacetylation of chitosan resulted in an observable increase in zeta potential but no apparent change in the particle size of ~300 nm. Both unmodified PLGA and chitosan-coated nanoparticles showed only slight cytotoxicity. Use of different temperatures and energy depletion suggested that the cellular uptake of both types of nanoparticles was energy-dependent. Further investigation revealed that the uptake of PLGA nanoparticles occurred via caveolin-mediated endocytosis and that of CS-PLGA nanoparticles involved both macropinocytosis and clathrin-mediated endocytosis, as evidenced by using endocytic inhibitors. However, under all conditions, CS-PLGA nanoparticles showed a greater potential to be transported into cells, as shown by flow cytometry and confocal microscopy. Transmembrane permeability analysis showed that unmodified and modified PLGA nanoparticles could improve the transport of exendin-4 by up to 8.9- and 16.5-fold, respectively, consistent with the evaluation in rats.Conclusion: The chitosan-coated nanoparticles have a higher transport potential over both free drug and unmodified particles, providing support for their potential development as a candidate oral delivery agent for exendin-4.Keywords: chitosan, PLGA, intestinal absorption" @default.
• W88596619 created "2016-06-24" @default.
• W88596619 creator A5004864084 @default.
• W88596619 creator A5024101693 @default.
• W88596619 creator A5031900556 @default.
• W88596619 creator A5032109161 @default.
• W88596619 creator A5034694052 @default.
• W88596619 creator A5039990370 @default.
• W88596619 creator A5049187488 @default.
• W88596619 creator A5053586953 @default.
• W88596619 creator A5067915562 @default.
• W88596619 creator A5091170515 @default.
• W88596619 date "2013-03-01" @default.
• W88596619 modified "2023-10-16" @default.
• W88596619 title "Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4" @default.
• W88596619 cites W1485563738 @default.
• W88596619 cites W1568216484 @default.
• W88596619 cites W170914365 @default.
• W88596619 cites W1893200055 @default.
• W88596619 cites W1970843696 @default.
• W88596619 cites W1971614155 @default.
• W88596619 cites W1975983454 @default.
• W88596619 cites W1977800073 @default.
• W88596619 cites W1978356367 @default.
• W88596619 cites W1978410646 @default.
• W88596619 cites W1984109621 @default.
• W88596619 cites W1988140617 @default.
• W88596619 cites W1991184308 @default.
• W88596619 cites W1993436544 @default.
• W88596619 cites W1993500226 @default.
• W88596619 cites W2000079001 @default.
• W88596619 cites W2003110090 @default.
• W88596619 cites W2003822740 @default.
• W88596619 cites W2014024725 @default.
• W88596619 cites W2023494010 @default.
• W88596619 cites W2025437344 @default.
• W88596619 cites W2027734531 @default.
• W88596619 cites W2028469454 @default.
• W88596619 cites W2033397840 @default.
• W88596619 cites W2038915015 @default.
• W88596619 cites W2039123138 @default.
• W88596619 cites W2040894400 @default.
• W88596619 cites W2046827775 @default.
• W88596619 cites W2055573906 @default.
• W88596619 cites W2072339204 @default.
• W88596619 cites W2079652953 @default.
• W88596619 cites W2079793032 @default.
• W88596619 cites W2086886701 @default.
• W88596619 cites W2087481863 @default.
• W88596619 cites W2113972541 @default.
• W88596619 cites W2146865072 @default.
• W88596619 cites W2152423174 @default.
• W88596619 cites W2159652632 @default.
• W88596619 doi "https://doi.org/10.2147/ijn.s41457" @default.
• W88596619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3607418" @default.
• W88596619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23658482" @default.
• W88596619 hasPublicationYear "2013" @default.
• W88596619 type Work @default.
• W88596619 sameAs 88596619 @default.
• W88596619 citedByCount "23" @default.
• W88596619 countsByYear W885966192015 @default.
• W88596619 countsByYear W885966192016 @default.
• W88596619 countsByYear W885966192017 @default.
• W88596619 countsByYear W885966192019 @default.
• W88596619 countsByYear W885966192020 @default.
• W88596619 countsByYear W885966192021 @default.
• W88596619 countsByYear W885966192022 @default.
• W88596619 countsByYear W885966192023 @default.
• W88596619 crossrefType "journal-article" @default.
• W88596619 hasAuthorship W88596619A5004864084 @default.
• W88596619 hasAuthorship W88596619A5024101693 @default.
• W88596619 hasAuthorship W88596619A5031900556 @default.
• W88596619 hasAuthorship W88596619A5032109161 @default.
• W88596619 hasAuthorship W88596619A5034694052 @default.
• W88596619 hasAuthorship W88596619A5039990370 @default.
• W88596619 hasAuthorship W88596619A5049187488 @default.
• W88596619 hasAuthorship W88596619A5053586953 @default.
• W88596619 hasAuthorship W88596619A5067915562 @default.
• W88596619 hasAuthorship W88596619A5091170515 @default.
• W88596619 hasBestOaLocation W885966191 @default.
• W88596619 hasConcept C13965031 @default.
• W88596619 hasConcept C150903083 @default.
• W88596619 hasConcept C155672457 @default.
• W88596619 hasConcept C171250308 @default.
• W88596619 hasConcept C185592680 @default.
• W88596619 hasConcept C192562407 @default.
• W88596619 hasConcept C207001950 @default.
• W88596619 hasConcept C2779732960 @default.
• W88596619 hasConcept C2780165375 @default.
• W88596619 hasConcept C55493867 @default.
• W88596619 hasConcept C71924100 @default.
• W88596619 hasConcept C86181022 @default.
• W88596619 hasConcept C86803240 @default.
• W88596619 hasConcept C98274493 @default.
• W88596619 hasConceptScore W88596619C13965031 @default.
• W88596619 hasConceptScore W88596619C150903083 @default.
• W88596619 hasConceptScore W88596619C155672457 @default.
• W88596619 hasConceptScore W88596619C171250308 @default.

• next